Skip to content
  • Pipeline
    • Pipeline overview
    • Clinical development
    • Drug delivery technology
  • News
  • About us
    • Team
    • Advisory Board
    • Board of Directors
  • Contact
  • Pipeline
    • Go back
    • Pipeline overview
    • Clinical development
    • Drug delivery technology
  • News
  • About us
    • Go back
    • Team
    • Advisory Board
    • Board of Directors
  • Contact

Author: hanna.stilling@iodigital.com

JM-010: Last patient enrolled in the ASTORIA Phase 2b clinical trial

Posted on 17. January 2024

CP-012: Dosing of first subject in Phase 1 trial

Posted on 27. September 2023

Abzu and Contera Pharma expand strategic partnership to add target identification to RNA-therapeutic design platform

Posted on 11. April 2023

Vernalis Research and Contera Pharma A/S announce a strategic collaboration

Posted on 27. September 2022

Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation

Posted on 8. September 2022

Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases using xAI technology

Posted on 7. July 2021

Contera Pharma elected new executive management team

Posted on 1. December 2020

Contera Pharma, subsidiary of Bukwang, raises 51 billion KRW in Series B financing round

Posted on 22. July 2020

Contera Pharma opens office in Seoul, Korea

Posted on 1. April 2020

Bukwang receives US FDA approval for JM-010 phase 2 clinical study IND

Posted on 14. February 2020

Posts pagination

Previous 1 2 3 4 Next

Contera Pharma ApS

Venlighedsvej 4

2970 Hørsholm

Denmark

Thomas Sager, CEO
info@conterapharma.com

  • Pipeline
  • News
  • About us
  • Contact
2026 Contera Pharma

Cookie & privacy policy

Whistleblower